Tempest Therapeutics (TPST) Stock Price, News & Analysis

Company Overview

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 as a monotherapy and in combination with immune checkpoint inhibitors for advanced solid tumors, including hepatocellular carcinoma. Tempest has also developed additional early-stage oncology programs, including TPST-1495, an investigational small-molecule inhibitor of cyclooxygenase enzymes.

Founded in 2018 and headquartered in the United States, Tempest advances its programs through clinical studies conducted in collaboration with medical centers and research partners. Its activities are primarily focused on the development of therapies for patients with advanced cancers rather than on commercialized products. Stephen Brady has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $0.68 to $0.75
• 50-Day Range: $0.68 to $1.21
• 52-Week Range: $0.68 to $12.23
• Volume: 228,061 shs
• Average Volume: 7.75 million shs
• Market Capitalization: $11.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Tempest Therapeutics Stock Analysis - MarketRank™

Tempest Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 842nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Tempest Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Tempest Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tempest Therapeutics are expected to decrease in the coming year, from ($0.83) to ($0.90) per share.

Price to Book Value per Share Ratio

Tempest Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.65% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently increased by 73.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempest Therapeutics does not currently pay a dividend.

Dividend Growth

Tempest Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.26

News Sentiment

Tempest Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tempest Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for TPST on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.20% of the stock of Tempest Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.52% of the stock of Tempest Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• AGM 2026: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TPST
• CIK: 1544227
• Web: www.tempesttx.com
• Phone: 415-798-8589
• Fax: N/A
• Employees: 4
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($4.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -576.56%
• Return on Assets: -134.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 16,890,000
• Free Float: 10,776,000
• Market Cap: $11.51 million
• Optionable: No Data
• Beta: -1.73